Directors

Alan-Raymond

Alan Raymond

Chairman, Non-Executive Director, Board Member

Dr Alan Raymond has 35 years of international marketing and general management experience within the pharmaceutical and biomedical industry. He has extensive Board level experience as a Non-Executive Director in both early-stage life science companies and NHS Trusts. In addition, Alan is a qualified Business and Executive Coach.

Alan is currently a Non-Executive Director with Diurnal Ltd and a Board advisor to the Patent Attorney firm, Symbiosis. Alan retired from full-time Executive roles in June 2014 as the Executive Sales and Marketing Director (and a shareholder) of Aesica Pharmaceuticals, a contract developer and manufacturer with a turnover of £180 million. Aesica Pharmaceuticals was recently acquired by Consort Medical Plc for a deal worth £233 million.  He took on the position of Chairman of AniPOC in January 2016.

Alan has a degree in Zoology and a PhD in invertebrate neurology from St Andrews University.


Richard-Littlehales

Richard Littlehales

CEO, Executive Director, Board Member

Richard is a City of London trained Chartered Accountant who for 20 years held CFO roles with a number of listed and private companies. He has led M&A activity, corporate fund-raising, stock exchange compliance and investor relations.  His passion is to bring big corporate standards of governance and operational excellence to emerging technology companies, and accordingly has spent the last 10 years focusing on the medical technology sector.

He has a first class honours degree in Economics and trained as a Chartered Accountant with Deloitte in London.  Richard is an experienced early stage CEO and brings a wealth of international corporate and commercial expertise to AniPOC.


Paul-Rush

Paul Rush

Operations, Non-Executive Director, Board Member

Paul commenced his career in the development of diagnostic tests in Serono Diagnostics during the period of 1985-1990 and then moved onto Guildhay Antisera Ltd designing reagents and diagnostic products for both the human and veterinary markets. Upon the sale of Guildhay, Paul co-founded Chromotech Ltd, a company focused on the development and commercialisation of Veterinary Diagnostics. Chromotech merged with Biochek BIH in 2003 and built a business with a turnover of €9.0 million with sales offices in UK, Holland, USA, Ukraine, Taiwan and China. Paul ran the UK operation and helped to establish a presence in USA. He has first-hand experience of setting up a successful veterinary diagnostic business and has amassed a wealth of knowledge of the product life cycle from product concept through to approval and licensing. Whilst at Biochek, he was instrumental in developing and commercialising over 25 diagnostic products for the poultry and porcine testing market.

Paul exited Biochek early January 2015 and was invited to join the board of AniPOC in January 2016. He has a degree in Microbiology from Nescot College Epsom.


Howard-Wilder

Howard Wilder

Commercial & Marketing, Non-Executive Director, Board Member

Howard is a seasoned executive with 30 years of experience in the Pharma business sector. He has held positions in sales, marketing, strategy formulation and general management, in small and multinational pharmaceutical and agribusinesses, predominantly in the B2B and B2C veterinary sector. He founded Genitrix in 1997 and grew the business into a top 20 UK veterinary pharmaceutical company which was exited via a trade sale to Dechra Pharmaceuticals PLC in December 2010. He subsequently held the office as the Executive Chairman of the laboratory services division of Dechra between 2010-2012. Howard has held a number of board level positions for start-ups and established companies.

Howard has a degree in Plant Science from Cardiff University and a MSc in Product Management and Marketing. He is a Chartered Director (IOD) and was awarded the director of the year award in 2009 and 2010.